PADOVA is a Phase IIb randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of prasinezumab for delaying motor progression in individuals with early PD on stale symptomatic therapy (L-dopa and MAOBi). Here, demographic and clinical baseline characteristics are presented, including a comparison between the MAOBi and L-dopa treated sub cohorts, as well as to the PASADENA population. One important aspect of this study is the novel primary endpoint, time to confirmed motor progression defined as 5 points on MDS-UPDRS Part III, chosen in order to assess change in the duration of the study.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.